UK Markets closed

Valneva SE (INRLF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
12.25-0.53 (-4.15%)
At close: 12:40PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close12.78
Open12.70
BidN/A x N/A
AskN/A x N/A
Day's range12.25 - 12.70
52-week range9.66 - 33.35
Volume450
Avg. volume481
Market cap1.289B
Beta (5Y monthly)0.87
PE ratio (TTM)N/A
EPS (TTM)-1.53
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Zacks

    Dynavax (DVAX) Up as EMA Accepts Valneva's COVID-19 Vaccine MAA

    Dynavax (DVAX) gains as the EMA accepts partner Valneva's MAA for COVID-19 vaccine.

  • Motley Fool

    Why Dynavax Stock Blasted 16% Higher Today

    What happened Several days after experiencing a pleasant share price pop on good regulatory news, Dynavax (NASDAQ: DVAX) repeated the feat on Thursday. An important partner for the company reported an encouraging development that morning, also in the regulatory sphere.

  • Globe Newswire

    EMA Accepts Filing of Marketing Authorization Application for Valneva’s Inactivated COVID-19 Vaccine Candidate

    Saint Herblain (France), May 19, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today confirmed that the European Medicines Agency (“EMA”) has accepted the filing of a marketing authorization application (MAA) for Valneva’s inactivated, whole-virus COVID-19 vaccine candidate, VLA2001. Acceptance of the MAA means VLA2001 is advancing from the rolling review process and beginning the formal review process by the EMA’s Committee for Human Medicinal Products (CHM